Literature DB >> 17344363

Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.

Yasmin Maor1, Galia Rahav, Natasha Belausov, Debby Ben-David, Gill Smollan, Nathan Keller.   

Abstract

Infections with S. aureus with heterogeneous intermediate resistance to vancomycin (hVISA) are occurring more frequently. The detection of these infections, their prevalence, clinical characteristics, and significance are controversial. During 2003 and 2004, all blood culture isolates of methicillin-resistant Staphylococcus aureus (264 patients) at the Sheba Medical Center, Tel Hashomer, Israel, were assessed for hVISA by using the Etest macromethod. A total of 16 patients (6%) were positive for hVISA. Resistance to teicoplanin alone and to vancomycin alone using the Etest macromethod was found in 14 and 10 patients, respectively. Standard MICs to vancomycin were between 1 to 4 mg/ml. Most of these isolates (12 of 16 [75%]) would have been missed without specific testing. The median number of bacteremic days was 4. Seven patients had positive blood cultures for more than 5 days. Twelve patients died, and for eight of these the deaths were directly related to hVISA sepsis. We found that hVISA bacteremia was prevalent in our institution, and we suggest seeking hVISA in patients with persistent S. aureus bacteremia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344363      PMCID: PMC1865872          DOI: 10.1128/JCM.01262-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System.

Authors: 
Journal:  Am J Infect Control       Date:  1999-12       Impact factor: 2.918

2.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 3.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin.

Authors:  P B Ward; P D Johnson; E A Grabsch; B C Mayall; M L Grayson
Journal:  Med J Aust       Date:  2001-11-05       Impact factor: 7.738

5.  A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.

Authors:  Fabien Garnier; Delphine Chainier; Timothy Walsh; Asa Karlsson; Anne Bolmström; Carole Grelaud; Marcelle Mounier; François Denis; Marie-Cécile Ploy
Journal:  J Antimicrob Chemother       Date:  2005-11-14       Impact factor: 5.790

Review 6.  Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.

Authors:  S K Fridkin
Journal:  Clin Infect Dis       Date:  2000-12-13       Impact factor: 9.079

7.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 8.  The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Timothy R Walsh; Robin A Howe
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

9.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

Review 10.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.

Authors:  F C Tenover; J W Biddle; M V Lancaster
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  36 in total

Review 1.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Authors:  Sarah W Satola; Monica M Farley; Karen F Anderson; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

3.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 4.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

5.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.

Authors:  Pierre Vaudaux; Elzbieta Huggler; Louis Bernard; Tristan Ferry; Adriana Renzoni; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

7.  Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?

Authors:  Kimberly C Claeys; Abdalhamid M Lagnf; Jessica A Hallesy; Matthew T Compton; Alison L Gravelin; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

8.  Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.

Authors:  Heather J Adam; Lisa Louie; Christine Watt; Denise Gravel; Elizabeth Bryce; Mark Loeb; Anne Matlow; Allison McGeer; Michael R Mulvey; Andrew E Simor
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

9.  Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.

Authors:  R K C Fong; J Low; T H Koh; A Kurup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-22       Impact factor: 3.267

10.  Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients.

Authors:  Yasmin Maor; Levona Lago; Amir Zlotkin; Yeshayahu Nitzan; Natasha Belausov; Debby Ben-David; Nathan Keller; Galia Rahav
Journal:  BMC Microbiol       Date:  2009-09-04       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.